Human Capital: The Leadership Difference
Health2047 Capital Partners has assembled a multi-discplinary team with significant accomplishments in company formation, healthcare, technology, and investing. Our managing partners have deep expertise in underwriting and managing investments across investment cycles and asset classes. And the company's connections to Health 2047 Inc. and the AMA provide unmatched situational awareness and expertise.
Douglass Given MD, PhD
Doug is Managing Partner at Health2047 Capital Partners LLC. He served as Health2047 Inc.’s Chief Executive from its founding in August of 2015 until January 2018. Previously, Doug spent more than a decade in venture capital as an Investment Partner and General Partner at life sciences investor Bay City Capital LLC participating in five sequential life sciences general funds and two sector-specific funds; he was associated with the partnership from 1999-2015. A physician and medical scientist by background, Doug has been a global corporate and operating executive at Lilly, Monsanto, Schering Plough and Mallinckrodt and a serial entrepreneur, as well as a venture capitalist. In addition to a number of private companies, he led three public biotechnology and biopharmaceutical companies as CEO.
Doug has served on more than 20 public and private boards. He is currently a Director at Health2047 Inc., Board Chair at Akiri Inc. and Arrowhead Pharmaceuticals Inc., Managing Partner at G5 Partners LLC, and serves on the board at First Mile Care Inc. and Vivaldi Biosciences Inc. He serves on advisory boards at the University of Chicago Medicine, Johns Hopkins Bloomberg School of Public Health, Stanford Medicine, Stanford Institute for Economic Policy Research (SIEPR), and The Houston Methodist Research Institute.
Doug received MD and PhD degrees from the University of Chicago, an MBA from the Wharton School at the University of Pennsylvania, and was a Clinical and Research Fellow in internal medicine and infectious diseases at Massachusetts General Hospital and Harvard Medical School.
Joseph A. Boystak
Joe has over 30 years of high-level investment banking, corporate development, and venture capital activities in the healthcare industry on a global scale. For the past decade, he has served as CEO of Brightwaters Capital, co-founding and advising companies developing disruptive technologies in healthcare, life sciences, and medical technology.
Over the course of his career, Joe has worked in the healthcare finance space with startups, Fortune 500 companies, and non-profit organizations involving various types of transactions with an aggregate value of approximately $10 Billion. He has co-founded and helped launch companies in the therapeutic, molecular diagnostic, medical technology, information technology, and artificial intelligence sectors out of top-tier academic medical centers including UCLA, Johns Hopkins, Harvard, and Memorial Sloan Kettering.
During his career in investment banking, Joe served as: Vice President of the Healthcare Finance Group at Dean Witter Reynolds; Global Head of Health Care Finance at Security Pacific Merchant Bank; Founding Managing Director and Group Head Healthcare Finance at Tucker Anthony Sutro; and Founding Managing Director and Group Head of Life Sciences at Jefferies & Co.
Joe holds a Master of Health Science from Johns Hopkins Bloomberg School of Public Health and a BA from Boston University. In addition, he serves on several corporate and non-profit boards including Omelet LLC, PAIGE.AI, SoCalBio, the UCLA Life Science Centennial Campaign, and the Johns Hopkins Bloomberg School of Public Health (on leave of absence until July 2018). Joe is also currently an advisor to Health2047 Inc. in the area of corporate finance.
Tom has more than 35 years of global and cross-industry experience that spans senior operating, venture investing, and strategic advisory roles. Tom is a proven business leader with a demonstrated track record of success developing new ideas, creating industry-level solutions, and building both public and private companies that scale globally. He has spent more than 15 years operating and advising privately financed companies, across a variety of roles including board member and CEO as well as senior executive positions in marketing, sales, engineering, service, and finance.
Tom also has deep roots in venture capital, having spent five years as a Global Partner at Arthur Andersen Ventures and General Partner in the Silicon Valley office of Venrock Associates where he served numerous venture-financed companies in various operating and advising capacities. Tom also spent three years as global head of strategy and technology at Arthur Andersen Business Consulting where he served the needs of clients across a board spectrum of industries and governmental authorities.
Tom has a B.S. and M.S. from the University of Illinois at Champaign-Urbana, a MBA from the Stanford Graduate School of Business, and completed the Corporate Strategy Executive Education program at Harvard Business School. He has served as a board member for over a dozen public and private companies and currently serves as an advisor to Health2047 Inc. in the area of technology business consulting. He served on Health2047 Inc.'s Board from November 2015 to January 2018. Tom’s other activities include serving on the leadership team of the American Medical Association’s Integrated Health Model Initiative.